This article is more than 5 years old. Information may no longer be current.
ASH Annual Meeting to highlight major advances in malignant, benign hematology
Click Here to Manage Email Alerts
SAN DIEGO — The HemOnc Today and Healio.com/HemOnc team will present comprehensive live coverage from the ASH Annual Meeting and Exposition beginning Dec. 3.
The meeting — expected to attract more than 27,000 attendees from around the world — will feature the latest clinical, basic and translational research related to hematologic malignancies and benign blood disorders.
“The ASH Annual Meeting is internationally notable for its unparalleled educational and scientific programming and its assortment of sessions on malignant and non-malignant hematology,” ASH President Charles S. Abrams, MD, of University of Pennsylvania, said in a press release. “What is so special about this meeting is that it serves as the largest meeting place for hematologists in the world. It is our largest stage for the year’s important discoveries, and it is the place where collaborations are formed. I am honored to welcome hematologists and other health professionals from all over the world to join us in San Diego.”
Nearly 5,000 scientific abstracts are scheduled for presentation during the 4-day meeting. They will spotlight the latest breakthroughs in treatment — including immunotherapy and gene therapy — as well as advances in prevention and diagnosis.
The program will include a plenary session on Dec. 4 and a late-breaking abstract session on Dec. 6. The conference also will include scientific forums and education sessions.
ASH Annual Meeting and Exposition content from HemOnc Today and Healio.com/HemOnc will include traditional articles and video commentaries.
We also will provide perspectives from experts who put study results in context and offer insights into how findings will affect patient care.
Our team will be onsite in San Diego throughout the meeting, so come back to Healio.com/HemOnc frequently for updates.